Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma
L. Jerby, C. Neftel, M. E. Shore, M. J. McBride, B. Haas, B. Izar, H. R. Weissman, A. Volorio, G. Boulay, L. Cironi, A. R. Richman, L. C. Broye, J. M. Gurski, C. C. Luo, R. Mylvaganam, , A. Regev
The paper profiles synovial sarcoma tumors to show that the SS18-SSX fusion drives oncogenic programs, which are repressed by immune cells and can be targeted with HDAC and CDK4/6 inhibitors.
bioRxiv · Aug 4, 2019 · PreprintCancer Biology